成人重症COVID-19患者肝素抗Xa活性与血栓弹力图的相关性
本研究为单中心回顾性研究,纳入2020-2021年重症COVID-19接受治疗性普通肝素输注的成人患者,且抗Xa与血栓弹力图(TEG)检测间隔≤2小时。主要终点为抗Xa与TEG反应(R)时间的相关性,采用Pearson系数及kappa一致性度量评估。
要点
- 重症COVID-19接受治疗性普通肝素时,抗Xa与TEG R时间相关性待明确。
- 抗Xa与TEG检测间隔需≤2小时方可纳入相关性分析。
- 次要终点包括aPTT与TEG R时间的相关性及临床结局。
核心结论
- 旨在评估重症COVID-19接受治疗性普通肝素输注患者抗Xa活性与TEG R时间的相关性。
研究设计与样本
- 单中心回顾性研究,为期15个月(2020-2021年),地点为学术医疗中心。
- 纳入成人重症COVID-19患者,接受治疗性普通肝素输注,且抗Xa与TEG检测间隔≤2小时。
关键数值与推荐
- 主要终点为抗Xa与TEG R时间的相关性,采用Pearson系数及kappa一致性度量评估。
- 次要终点包括aPTT与TEG R时间的相关性及临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: Severe coronavirus disease 2019 (COVID-19) increases the risk of thrombotic complications with unfractionated heparin (UFH) as a commonly used agent in managing venous thromboembolism (VTE). The optimal anticoagulation intensity and monitoring parameters in intensive care unit (ICU) COVID-19 patients remains controversial. The primary study aim was to evaluate the relationship between anti-Xa and thromboelastography (TEG) reaction (R) time in patients with severe COVID-19 receiving therapeutic UFH infusions. DESIGN: Single-center, retrospective study conducted over a 15-month period (2020-2021). SETTING: Academic medical center (Banner University Medical Center Phoenix). PATIENTS: Adult patients with severe COVID-19 administered therapeutic UFH infusions with one or more corresponding TEG, and anti-Xa assessments drawn within ≤2 hours of each other were included. The primary end point was the correlation between anti-Xa and TEG R time. Secondary aims were to describe the correlation between activated partial thromboplastin time (aPTT) and TEG R time, as well as clinical outcomes. Pearson's coefficient was used to evaluate the correlation using a kappa measure of agreement.
引用
- Buckley MS, Benanti GE, Gilbert B, et al. Correlation between heparin anti-Xa activity and thromboelastography in adult critically ill COVID-19 patients. Pharmacotherapy. 2023. PMID: 37199139. doi:10.1002/phar.2829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。